New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 20, 2013
12:51 EDTIAU, FE, LINE, VRTX, CTL, SFDIncreasing implied volatility stocks: SFD VRTX FE CTL LINE IAU
News For SFD;VRTX;FE;CTL;LINE;IAU From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 28, 2015
09:00 EDTVRTXPfizer has 'significant capacity' for additional deals, says JPMorgan
Subscribe for More Information
May 22, 2015
16:13 EDTFEFirstEnergy files automatic mixed securities shelf
Subscribe for More Information
May 21, 2015
11:04 EDTVRTXVertex has conference call hosted by JPMorgan
JPMorgan Analyst Kasimov hosts a conference call with CFO Ian Smith on May 26 at 1 pm.
10:30 EDTVRTXVertex management to meet with Maxim
Subscribe for More Information
May 20, 2015
08:07 EDTFEFirstEnergy to hold a meeting
Fixed Income Investor Meeting is being held in New York on May 20 at 11 am.
May 19, 2015
09:22 EDTLINEOn The Fly: Pre-market Movers
Subscribe for More Information
07:56 EDTVRTXGilead for Achillion rumor not ridiculous, but highly unlikely, TheStreet says
Subscribe for More Information
07:44 EDTLINELINN Energy 16M share Spot Secondary priced at $11.79
Raymond James, BofA/Merrill, Barclays, Citigroup, Credit Suisse, JPMorgan, Morgan Stanley and RBC Capital acted as joint book running managers for the offering.
May 18, 2015
19:12 EDTLINEOn The Fly: After Hours Movers
Subscribe for More Information
16:23 EDTLINELINN Energy files 16M units representing limited liability company interests
Subscribe for More Information
10:01 EDTLINEOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:51 EDTLINELINN Energy downgraded to Sell from Neutral at Goldman
Subscribe for More Information
May 17, 2015
13:46 EDTVRTXVertex reports Orkambi data, says 'significant improvements' in primary endpoint
Vertex Pharmaceuticals announced that the New England Journal of Medicine published data from the two phase 3 studies of Orkambi, or lumacaftor/ivacaftor, a medicine designed to treat the underlying cause of cystic fibrosis in people ages 12 and older with two copies of the F508del mutation. In November 2014, Vertex submitted an NDA to the FDA for the combination of lumacaftor and ivacaftor. On May 12th, the FDA’s Pulmonary Allergy Drugs Advisory Committee voted 12-1 to recommend approval of Orkambi for people ages 12 and older with two copies of the F508del mutation. The FDA is expected to make a decision by July 5. The New England Journal reports that the studies enrolled 1108 patients who underwent randomization and received Orkambi. In both studies, there were significant improvements in the primary end point in both lumacaftor–ivacaftor dose groups. The difference between active treatment and placebo with respect to the mean absolute improvement in the percentage of predicted FEV ranged 2.6%-4%, which corresponded to a mean relative treatment difference of 4.3 to 6.7%. Pooled analyses showed that the rate of pulmonary exacerbations was 30%-39% lower than in the placebo group. The rate of events leading to hospitalization or the use of intravenous antibiotics was also lower. The incidence of adverse events was generally similar to the placebo group.
May 15, 2015
09:31 EDTVRTXAmerican Thoracic Society to hold a conference
ATS 2015 Conference is being held in Denver on May 15-20.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use